These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22519528)

  • 21. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang E
    Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
    Farnier M
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):145-52. PubMed ID: 21619378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
    Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
    J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The PCSK9 decade.
    Lambert G; Sjouke B; Choque B; Kastelein JJ; Hovingh GK
    J Lipid Res; 2012 Dec; 53(12):2515-24. PubMed ID: 22811413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).
    Ferdinand KC; Nasser SA
    Cardiovasc Drugs Ther; 2015 Jun; 29(3):295-308. PubMed ID: 26068408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
    Awan Z; Baass A; Genest J
    Clin Chem; 2014 Nov; 60(11):1380-9. PubMed ID: 25248569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P; Just IA; Kaschina E
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PCSK9: From discovery to therapeutic applications.
    Farnier M
    Arch Cardiovasc Dis; 2014 Jan; 107(1):58-66. PubMed ID: 24373748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PCSK9 inhibition in patients with hypercholesterolemia.
    Desai NR; Sabatine MS
    Trends Cardiovasc Med; 2015 Oct; 25(7):567-74. PubMed ID: 25771732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
    Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I
    Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.
    Stein EA; Swergold GD
    Curr Atheroscler Rep; 2013 Mar; 15(3):310. PubMed ID: 23371064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCSK9 inhibitors: the next frontier in low-density lipoprotein lowering.
    Jialal I; Patel SB
    Metab Syndr Relat Disord; 2015 Apr; 13(3):99-101. PubMed ID: 25734961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
    Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCSK9 antibodies for the treatment of hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Nutrients; 2014 Dec; 6(12):5517-33. PubMed ID: 25470376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
    Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PCSK9 inhibitors: an overview on a new promising lipid-lowering therapy.
    Denegri A; Petrova-Slater I; Pasotti E; Rossi MG; Pedrazzini GB; Moccetti T; Moccetti M
    J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):237-44. PubMed ID: 26855411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering.
    Mitchell T; Chao G; Sitkoff D; Lo F; Monshizadegan H; Meyers D; Low S; Russo K; DiBella R; Denhez F; Gao M; Myers J; Duke G; Witmer M; Miao B; Ho SP; Khan J; Parker RA
    J Pharmacol Exp Ther; 2014 Aug; 350(2):412-24. PubMed ID: 24917546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.